Post-COVID-19, India needs to strengthen its pharma R&D ecosystem to tap into emerging drug development opportunities and changing paradigms in the new drug development framework.....

Sanjay Singh, Partner – Deal Advisory, Head of Lifesciences, KPMG in India, identifies new generics opportunities, established manufacturing ecosystem, growing penetration of health insurance and ta...